How peptides work
Peptides are signaling molecules. They don't do the work themselves — they tell your cells to do it. Understanding that single distinction explains most of what peptide therapy is and isn't.
Peptides are messages, not workers
It helps to think of your body as a giant communication network. Different tissues need to coordinate — muscle needs glucose when you move, the pancreas needs to release insulin when glucose is in your blood, the immune system needs to ramp up during infection. The way all of that gets coordinated is through signals.
Peptide hormones and neuropeptides are one of the main signal types your body uses. A cell releases a peptide, it travels (sometimes just across a synapse, sometimes through the bloodstream), it binds a receptor on another cell, and that binding event tells the receiving cell to do something.
Therapeutic peptides work the same way. They're not doing a biochemical job themselves — they're sending instructions to cells that then do the job. That's why they tend to be effective at small doses: a single peptide molecule, binding a single receptor, can trigger a cascade inside the cell that amplifies the signal many thousand-fold.
Receptor binding — the starting point
G-protein coupled receptors
The largest family of peptide receptors — GLP-1, GIP, GHRH, and hundreds of others all bind GPCRs on the cell surface. When a peptide binds, the receptor changes shape, activating a G-protein on the inside of the cell membrane, which triggers the downstream signaling cascade.
Insulin-type receptors
Insulin and IGF-1 bind receptor tyrosine kinases. Instead of activating a G-protein, ligand binding activates an enzyme domain on the inside of the cell membrane, which phosphorylates a set of downstream proteins that regulate glucose uptake, growth, and metabolism.
Direct gating
Some peptides directly open or close membrane ion channels. The effect is typically faster than GPCR signaling and shorter-lived. (Selank, sometimes cited in this category, actually modulates GABAergic signaling indirectly — through enkephalinase inhibition that raises endogenous GABA levels rather than direct channel gating. See the Selank research page for mechanism details.)
After crossing membranes
A smaller number of therapeutic peptides act inside the cell, often after being taken up by specific transporters or endocytosis. The delivery challenge is significant, which is part of why most peptide drugs act at cell-surface receptors rather than intracellular targets.
Why small doses matter: amplification
One peptide binding one receptor can trigger the activation of hundreds of downstream enzymes, each of which can generate thousands of second-messenger molecules, each of which activates many more downstream proteins. The biological signal at the end of this cascade is massively amplified compared with the initial binding event.
That's why peptides can be effective at microgram-level doses. You don't need a lot of signal — you just need the signal to arrive and bind the right receptor. The cellular machinery does the rest.
It's also why specificity matters so much. A poorly targeted peptide that binds the wrong receptor will still trigger amplified downstream effects — just the wrong ones. Selectivity in peptide design is engineering for where the amplification happens.
Short half-lives are a feature
Your body clears most native peptides within minutes. That sounds like a pharmacological bug, but biologically it's the whole point. Most peptide hormones signal in pulses rather than at constant levels — a burst of signal followed by a return to baseline, then another burst. Tonic (always-on) signaling often produces the opposite effect of pulsatile signaling because receptors desensitize when they're continuously stimulated.
Growth hormone is the classic example. GH is released in a few large pulses during the day, with the biggest one coming during slow-wave sleep. Exogenously administering GH as a continuous drip produces a very different metabolic response than matching the natural pulse pattern. This is why sermorelin, which amplifies existing GH pulses, is pharmacologically distinct from recombinant HGH, which delivers sustained high levels.
When drug designers extend a peptide's half-life (e.g., semaglutide's 7-day half-life versus native GLP-1's ~2-minute half-life), they're making a specific decision: accept some loss of pulsatile signaling in exchange for convenient dosing. That trade-off is different for every drug.
Peptides vs small-molecule drugs
Both can be effective therapies. They behave differently.
Selectivity — peptides usually win
A peptide drug typically has a much more specific fit with its target receptor than a small molecule does. That translates to fewer off-target effects, which is part of why GLP-1 agonists tend to produce fewer systemic side effects than older weight-loss drugs that relied on small-molecule pharmacology.
Delivery — small molecules usually win
Most small molecules can be taken orally, shelf-stored at room temperature, and manufactured cheaply. Peptides usually need injection, refrigeration, and specialized synthesis. Delivery remains peptides' biggest weakness.
Complexity of target — peptides reach further
Many receptors and protein-protein interactions are “undruggable” by small molecules — their binding surfaces are too broad or too flat for a small molecule to grip. Peptides can engage these targets through their multiple contact points, which is why peptide therapeutics are a growing focus in oncology, immunology, and metabolic disease research.
Practical implications for patients
A few things follow from the mechanism that shape how peptide therapy feels in practice.
Timing often matters. Because many peptides work with natural pulse cycles, some are dosed at specific times of day — sermorelin at bedtime, for example. Your clinician will explain the reasoning for your specific protocol.
Onset varies. Some peptides produce effects within hours (oxytocin, ACTH). Others take weeks of regular dosing before downstream effects are clinically apparent (GLP-1 agonists, sermorelin). This isn't inconsistency — it's because the downstream effect you care about may be several layers of biology past the immediate signal.
Side effects usually track the mechanism. GLP-1 agonists slow gastric emptying — which is part of why they reduce appetite — so GI side effects are the main complaint. Sermorelin amplifies GH release, so its adverse effects are in the same neighborhood as GH biology. Knowing the mechanism helps you predict what a side-effect profile is likely to look like before you start.
Keep reading
Compounding & the law
How pharmacy compounding works, why some peptides can be prescribed and others can't, and what FDA Category 2 actually means.
The Peptide Library
See how these mechanisms play out for specific peptides — semaglutide, tirzepatide, sermorelin, NAD+, and the Tier 2 compounds pending FDA reclassification.